Alphatec Spine appoints Jeffrey G. Black as CFO
Mr. Black is a seasoned executive with over 25 years of experience in financial and operations management, including senior-level finance roles for six publicly-traded companies.
Mr. Black previously served as the Chief Financial Officer of Applied Proteomics, Inc., a company that develops novel, non-invasive diagnostics using a proteomics-based platform.
Before joining Applied Proteomics, he served as the Chief Financial Officer of AltheaDx, Inc., a molecular diagnostics company specializing in pharmacogenetic testing.
Prior to AltheaDx, Mr. Black served as Chief Financial Officer of Verenium Corporation (formerly Diversa Corporation), a Nasdaq-listed pioneer in the development and commercialization of high-performance enzymes for use in industrial processes.
During his nine-year tenure at Verenium/Diversa, he played a leadership role in more than $500 million of strategic, equity, and debt financing transactions, culminating in the sale of the company to BASF in 2013.
Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP.
He currently serves on the Board of Directors of Cellana, Inc., a privately-held algae bioproducts company. ■
LATEST MOVES FROM California
- ChromaDex appoints Steven Rubin to board
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
More inside POST
Lukoil Q4 sales increased 7% Earnings